Day: June 25, 2025

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company (the “Common Shares”). Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of...

HONG KONG, June 26, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Celia Yan has joined the firm as a Partner and Head of Hybrid for Asia Pacific. Based in Hong Kong, Yan will lead the expansion of Apollo’s hybrid platform across the region, building on the firm’s momentum in delivering flexible, tailored capital solutions across private markets. Apollo’s hybrid business focuses on delivering creative, partnership-driven solutions that sit between traditional debt and equity. We provide solutions that help companies fund growth initiatives, generate liquidity and deleverage balance sheets, among other bespoke applications. In this newly created role, Yan will drive origination, execution and growth for Apollo’s hybrid strategies in Asia Pacific. Yan brings over 20 years of industry experience and extensive private...

MCLEAN, Va., June 25, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today posted to its website its Monthly Volume Summary for May 2025, which provides information on Freddie Mac’s mortgage-related portfolios, securities issuance, risk management, delinquencies, debt activities and other investments. Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn more: Website | Consumers | LinkedIn | Facebook| X | Instagram | YouTube MEDIA CONTACT: Fred Solomon703-903-3861Frederick_Solomon@FreddieMac.com INVESTOR CONTACT: Mahesh Lal571-382-3630

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses. Private Placement Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the “Warrants”) to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of $0.25 per Warrant. The PIPE included a syndicate of world-class investors including Vor Bio’s existing stockholder RA Capital Management, as well as Mingxin Capital, Forbion, Venrock Healthcare...

–Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties -Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global...

REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) — The 2025 Annual and Extraordinary General Meeting (the “2025 AGM”) of Alvotech (the “Company”) was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.  All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: https://investors.alvotech.com/corporate-governance/annual-general-meeting-2025 Alvotech Investor Relations Benedikt Stefanssonalvotech.ir@alvotech.com

The 2025 Annual and Extraordinary General Meeting (the “2025 AGM”) of Alvotech (the “Company”) was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.  All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: https://investors.alvotech.com/corporate-governance/annual-general-meeting-2025 Alvotech Investor Relations Benedikt Stefansson alvotech.ir@alvotech.com

NurseMagic™ V3.0 uniquely addresses the needs of approximately 20% of U.S. nurses in the U.S. with AI-powered charting in their native language DETROIT, June 25, 2025 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced that its flagship app, NurseMagic™, now supports charting in 16 languages. This major enhancement is designed to address a key barrier to success for nearly 1 million nurses in the U.S. who speak English as a second language (ESL) — accounting for 19.2% of the nursing workforce — and to chart more efficiently and with greater confidence. This multilingual capability positions Amesite to meet immediate market needs. Markets now able to leverage the platform include:ESL nurses in the United States: Nearly 20% of U.S. nurses have English...

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce the results of its Shareholder Meeting (the “Meeting”). A total of 57,044,319 common shares, representing 52.60% of the issued and outstanding common shares of the Company, were represented at the Meeting. Six (6) directors were elected to the Company’s board for the ensuing year. The following is a tabulation of the votes submitted in person and by proxy:Director Nominee # of Votes in Favour % of Votes in Favour # of Votes Withheld % of Votes WithheldCatherine Flax 55,679,343   97.761%   1,274,976   2.239%  Margot Naudie 53,811,527   94.842%   2,926,814   5.158%  Bruce...